NEW YORK (TheStreet) -- Shares of Mylan Inc. (MYL) - Get Mylan N.V. (MYL) Report  are up 0.25% to $52.50 in after-hours trading after reporting third quarter earnings per share of $1.16, up from 82 cents for the same period a year ago.

Revenues of the global pharmaceutical company were up 18% to $2.08 billion from $1.77 billion a year ago.

The company increased its guidance range for the 2014 full year to $3.54 to $3.60, according to CEO Heather Bresch.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

"During the third quarter, we saw double-digit revenue growth in North America, Rest of World and our Specialty segment, and we continued to execute against our growth drivers, with strong contributions from our injectables and anti-retroviral franchises, as well as from EpiPen® Auto-Injector," Bresch said.

Additionally, Mylan announced today the U.S. launch of its Nevirapine extended-release tablets, 400 mg, which is the generic version of Boehringer Ingelheim's Viramune XR, a combination antiretroviral (ARV) treatment of HIV-1 infection.

TheStreet Recommends

Separately, TheStreet Ratings team rates MYLAN INC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate MYLAN INC (MYL) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

You can view the full analysis from the report here: MYL Ratings Report

MYL data by YCharts

Image placeholder title

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.